BIOMAT Database Logo BIOMAT Database Logo

Vertical transmission of HIV-1 variants resistant to reverse transcriptase and protease inhibitors. 2001

M I De Jose, and J T Ramos, and S Alvarez, and J L Jimenez, and M A Muñoz-Fernández

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018445 Infectious Disease Transmission, Vertical The transmission of infectious disease or pathogens from one generation to another. It includes transmission in utero or intrapartum by exposure to blood and secretions, and postpartum exposure via breastfeeding. Fetomaternal Infection Transmission,Infection Transmission, Fetomaternal,Infection Transmission, Maternal-Fetal,Infection Transmission, Vertical,Maternal-Fetal Infection Transmission,Mother-to-Child Transmission,Pathogen Transmission, Vertical,Vertical Infection Transmission,Vertical Infectious Disease Transmission,Vertical Transmission of Infectious Disease,Infection Transmission, Maternal Fetal,Maternal Fetal Infection Transmission,Mother to Child Transmission,Mother-to-Child Transmissions,Transmission, Fetomaternal Infection,Transmission, Maternal-Fetal Infection,Transmission, Mother-to-Child,Transmission, Vertical Infection,Transmission, Vertical Pathogen,Transmissions, Mother-to-Child,Vertical Pathogen Transmission
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

M I De Jose, and J T Ramos, and S Alvarez, and J L Jimenez, and M A Muñoz-Fernández
Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.
July 1998, The New England journal of medicine,
M I De Jose, and J T Ramos, and S Alvarez, and J L Jimenez, and M A Muñoz-Fernández
In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.
February 2015, AIDS research and human retroviruses,
M I De Jose, and J T Ramos, and S Alvarez, and J L Jimenez, and M A Muñoz-Fernández
Inhibitors from natural products to HIV-1 reverse transcriptase, protease and integrase.
December 2010, Mini reviews in medicinal chemistry,
M I De Jose, and J T Ramos, and S Alvarez, and J L Jimenez, and M A Muñoz-Fernández
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.
January 2000, AIDS reviews,
M I De Jose, and J T Ramos, and S Alvarez, and J L Jimenez, and M A Muñoz-Fernández
HIV-1 reverse transcriptase inhibitors.
June 2007, Applied microbiology and biotechnology,
M I De Jose, and J T Ramos, and S Alvarez, and J L Jimenez, and M A Muñoz-Fernández
Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.
December 1999, Journal of medical virology,
M I De Jose, and J T Ramos, and S Alvarez, and J L Jimenez, and M A Muñoz-Fernández
[Inhibitors of HIV-1 reverse transcriptase and protease as chemotherapeutics for AIDS].
September 1991, Nihon rinsho. Japanese journal of clinical medicine,
M I De Jose, and J T Ramos, and S Alvarez, and J L Jimenez, and M A Muñoz-Fernández
Fullerene derivatives as dual inhibitors of HIV-1 reverse transcriptase and protease.
January 2021, Bioorganic & medicinal chemistry letters,
M I De Jose, and J T Ramos, and S Alvarez, and J L Jimenez, and M A Muñoz-Fernández
[Recent development of novel reverse transcriptase inhibitors and protease inhibitors against HIV-1 infection].
March 2010, Nihon rinsho. Japanese journal of clinical medicine,
M I De Jose, and J T Ramos, and S Alvarez, and J L Jimenez, and M A Muñoz-Fernández
Inhibitors of HIV-1 reverse transcriptase.
January 2008, Advances in pharmacology (San Diego, Calif.),
Copied contents to your clipboard!